SCHEMBL26549546

SCHEMBL26549546

CCCC(C)Nc1ccc(COC(=O)C(C)(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
KMT2A Q03164 4/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 3/20 0.38
ALDH1A1 P00352 4/20 0.38
TP53 P04637 1/20 0.38
HSP90AA1 P07900 1/20 0.38
CYP3A4 P08684 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38
HIF1A Q16665 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
POLB P06746 2/20 0.37
ACACB O00763 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1753750 0.84 ROCK2 (0.43) ROCK2KMT2AL3MBTL1SMN1; SMN2MEN1
SCHEMBL22947330 0.82 ELANE (0.41) CA1CA2TP53CYP3A4ALOX15
SCHEMBL23318499 0.82 ROCK2 (0.42) ROCK2KMT2AL3MBTL1SMN1; SMN2MEN1
SCHEMBL22947672 0.81 CA1 (0.37) CA1CA2KMT2AL3MBTL1SMN1; SMN2
SCHEMBL19201796 0.80 ROCK2 (0.43) ROCK2KMT2AL3MBTL1SMN1; SMN2MEN1
SCHEMBL25608702 0.79 CA1 (0.36) CA1CA2KMT2AL3MBTL1SMN1; SMN2
SCHEMBL25046481 0.79 SMN1; SMN2 (0.46) ROCK2CA1CA2KMT2AL3MBTL1
SCHEMBL12157064 0.78 KMT2A (0.43) ROCK2KMT2AL3MBTL1SMN1; SMN2MEN1
SCHEMBL1753582 0.77 MEN1 (0.54) ROCK2KMT2AL3MBTL1SMN1; SMN2MEN1
SCHEMBL19901428 0.77 MEN1 (0.54) ROCK2KMT2AL3MBTL1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330242-A1 IMMUNOCONJUGATES AND METHODS IMMUNOME, INC. 2023-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330242-A1 IMMUNOCONJUGATES AND METHODS CD4, L1CAM, PDCD1LG2 ROCK2 4387/4885CA1 3274/4885CA2 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.